Tests to check for bladder cancer include physical exams, urine tests, and imaging. Biopsy or cystoscopy may help confirm a diagnosis. If you’re at high risk, at-home tests might help you screen ...

Most of oncology has moved to a pathway based on biopsy and imaging followed ... or MIBC at the time of flexible cystoscopy is an important component of your bladder cancer staging pathway.

If we include patients who demonstrated an indeterminate response defined as negative cystoscopy and positive urine cytology without a confirmatory negative bladder biopsy, the total response ...

1–3 Standard management approaches include outpatient flexible cystoscopy, followed by transurethral resection of bladder tumour (TURBT), 4 which ... to correct treatment using an outpatient biopsy ...

Dr. Param Mariappan presented a study of Bladder Epicheck-triggered photodynamic diagnosis biopsies for the detection of high-grade recurrences missed by white light cystoscopy (WLC ... using ...

The primary end point was complete response (CR) at 6 months, defined as “proportion of patients who are disease free within the bladder by cystoscopy (with or without biopsy) and urinary cytology.” ...

Traditional diagnostic methods, such as cystoscopy and urine cytology ... making it a versatile tool for liquid biopsy. In contrast, urine ctDNA is specifically valuable for diagnosing and monitoring ...

The initial biopsy was inconclusive, and so imaging was repeated a month later, showing the bladder mass had altered in position, which was confirmed at cystoscopy. Biopsy confirmed the diagnosis of ...

Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...

A urinary DNA methylation test showed potential for detecting high-grade or invasive bladder cancer, according to results of a prospective multicenter study.The approach — which outperformed the ...

OSLO, Norway, March 14, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study "Oncologic Outcomes of Blue Light Cystoscopy in an Equal ...